[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559490":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":55,"collaborators":25,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":25,"eligibilityCriteria":63,"healthyVolunteers":60,"sex":64,"minAge":65,"maxAge":25,"enrollmentInfo":66,"targetDuration":25,"studyType":69,"phases":70,"briefSummary":72,"conditions":73,"keywords":25,"overallStatus":40,"whyStopped":25,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Universidad Autonoma de Nuevo Leon","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"intralesional Triamcinolone","ACTIVE_COMPARATOR","Triamcinolone acetonide will be administered intralesionally at a concentration of 4 mg\u002FmL. The solution will be injected in 0.1 mL doses, spaced 1 cm apart. The maximum total dose per session will be limited to 3 mL",[13],"Drug: Candida Albicans Antigen Injection",{"label":15,"type":16,"description":17,"interventionNames":18},"Candida albicans antigen","EXPERIMENTAL","Single subcutaneous administration of 0.1 mL of Candida albicans antigen into one of the alopecic patches",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Candida Albicans Antigen Injection","subcutaneous administration of Candida albicans antigen",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Fania Muñoz Garza, PhD","Hospital Universitario \"Dr. José E. González\"","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"Erika Alba-Rojas, MD","CONTACT","+528183891111","eri9ar@yahoo.com",[38],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Hospital Universitario \"Dr. José Eleuterio González\"","RECRUITING","Monterrey","Nuevo León","64460","Mexico","MX",{"type":47,"coordinates":48},"Point",[49,50],-100.31721,25.68435,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":35,"phoneExt":25,"email":36},"Erika Alba Rojas, MD",{"type":30,"investigatorFullName":56,"investigatorTitle":57,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Erika Lizbeth Alba Rojas","Erika Alba Rojas","100559490","clinical-trial-on-the-efficacy-of-intralesional-triamcinolone-versus-candida-albicans-antigen-in-treating-alopecia-areata-100559490",false,"NCT06564805","Clinical Trial on the Efficacy of Intralesional Triamcinolone Versus Candida Albicans Antigen in Treating Alopecia Areata","Inclusion Criteria:\n\n* Diagnosis of alopecia areata\n* SALT score of less than 50% extension\n* Has not received any topical or systemic treatment in the last month\n* Signed informed consent\n\nExclusion Criteria:\n\n* Any skin condition on the scalp (infectious, inflammatory or neoplastic) that could modify the clinical of trichoscopic features\n* Pregnancy or breast-feeding\n* Patients in medications that could cause hair loss as side-effects","ALL","6 Years",{"count":67,"type":68},30,"ESTIMATED","INTERVENTIONAL",[71],"NA","The efficacy of two intralesional treatment modalities for alopecia areata will be determined. Thirty patients over the age of 6 with the diagnosis of alopecia areata on the scalp, with an extension of less than 50%, will be included. A comparison will be made between the effectiveness of intralesional Triamcinolone (standard first-line treatment) and intralesional Candida albicans antigen, with serial clinical and trichoscopic pictures at follow-up to evaluate the clinical response and associated adverse effects.",[74],"Alopecia Areata","2024-08-19",{"date":77,"type":78},"2024-08-21","ACTUAL",{"date":80,"type":78},"2024-08-20",{"date":82,"type":68},"2025-12-31",{"name":5,"class":6},1]